OBJECTIVES: Sacral neuromodulation (SNM) may improve @entity2335 / @entity2336 (IC/BPS) symptoms of urinary frequency, urgency and perhaps even @entity158 , but objective measures of improvement are lacking. We evaluated the potential for urinary chemokines to serve as measures of treatment response over time to SNM. METHODS: @entity1 with IC/BPS undergoing SNM consented for this study. Three-day bladder/ @entity158 diaries were collected at baseline and validated @entity2335 Symptom Problem Index (ICSPI) scores and mid-stream urine specimens were collected at baseline and at 24   weeks after successful implant. Collected urine was screened for @entity281 by dipstick and analyzed for chemokines by luminex xMAP analysis. RESULTS: At baseline (n   =   16), urine levels of @entity2851 positively correlated with @entity158 score (r   =   0.63, P   =   0.009), urgency (r   =   0.61, P   =   0.01), ICSPI (r   =   0.43, P   =   0.09) and daily voids (r   =   0.44, P   =   0.08). ICSPI and @entity158 scores also positively correlated with sIL-1ra (r   =   0.50, P   =   0.04) and @entity2842 ( @entity2842 ) or @entity2842 positively correlated with daily voids (r   =   0.45, P   =   0.07) only. At 24   weeks, the median ICSPI index fell from 28 to 15 (n   =   7, P   =   0.008). Urine levels of sIL-1ra (633.8        188.2 vs. 149.9        41.62   pg/mL) and @entity2842 (448.3        11.6 vs. 176.9        46.16   pg/mL) and @entity5737 (20.78        4.09 vs. 11.21        4.12   pg/mL) were also significantly reduced at the follow-up relative to baseline values (P   =   0.04). Multivariable analysis of data revealed that sIL-1ra and @entity2842 together explained the majority of variance in data. Levels of @entity2851 , @entity371 , @entity687 , @entity7 ( @entity7 ), platelet-derived growth factor (PDGF) were also reduced at 24   weeks, but differences were not significant. CONCLUSIONS: Concomitant decrease in urine levels of chemokines especially @entity2842 was associated with treatment response of SNM. These results support the role of chemokines as downstream effectors of neuromodulation response and could serve as potential non-invasive measures of treatment response. CLINICAL TRIAL REGISTRATION NUMBER: NCT01739946.

Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in XXXX / @entity2336 @entity1 .

@entity1 :: ('9606', 'Species') :: ['Women'] @entity5737 :: ('6352', 'Gene') :: ['CCL5'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity2851 :: ('2919', 'Gene') :: ['CXCL-1'] @entity2336 :: ('MESH:D018856', 'Disease') :: ['painful bladder syndrome'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity2842 :: ('6347', 'Gene') :: ['monocyte chemotactic protein-1', 'MCP-1', 'CCL2'] @entity687 :: ('3576', 'Gene') :: ['interleukin (IL)-8'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity371 :: ('3627', 'Gene') :: ['CXCL-10'] @entity2335 :: ('MESH:D003556', 'Disease') :: ['Interstitial Cystitis', 'interstitial cystitis']
@entity2335 :: (MESH:D003556,Disease) :: ['Interstitial Cystitis']
